Findings from the phase 3 MATTERHORN trial supported the FDA approval of perioperative durvalumab for resectable gastric and GEJ cancers.

Extensive safety testing and manufacturing improvements have now made it possible to bring the drug back to the US market.

Childhood exposure linked to modestly better cognition in secondary school, but no significant difference seen at age ~60 years.

HealthDay News — Eli Lilly reached a major milestone Friday, becoming the first healthcare company in the world to hit a $1 trillion market value. The drug company briefly crossed the trillion-dollar ...